Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women

Journal of Infectious Diseases

Volumn 207, Issue 11, 2013, Pages 1723-1729

  Konopnicki, Deborah ^a   Manigart, Yannick ^a   Gilles, Christine ^a   Barlow, Patricia ^a   De Marchin, Jérome ^b   Feoli, Francesco ^c   Larsimont, Denis ^c   Delforge, Marc ^a   De Wit, Stéphane ^a   Clumeck, Nathan ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b Molecular Biology Laboratory   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

CD4 count; cervix; HIV; HPV; HPV Clearance; HPV Persistence; Immune reconstitution; prevalence; Sustained undetectable viral load; women

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; DISEASE DURATION; ETHNICITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; UTERINE CERVICITIS; VIRUS INHIBITION; VIRUS LOAD;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84877309629     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit090     Document Type: Article

References (27)

1. Sun X, Kuhn L, Ellerbrock T, Chiasson M, Bush T, Wright T. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337:1343-9.
2. Ahdieh L, Klein R, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001; 184:682-90.
3. Palefsky JM. Cervical human papillomavirus infection and cervical intraepithelial neoplasia and cancer in the era of highly active antiretroviral therapy. Curr Opin Oncol 2003; 15:382-8.
4. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577-86.
5. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547-51.
6. Del Mistro A, Bertorelle R, Franzetti M, et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 2004; 38:737-42.
7. Paramsothy P, Jamieson D, Heilig C, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009; 113:26-31.
8. Shrestha S, Sudenga S, Smith J, Bachmann L, Wilson C, Kempf M. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis 2010; 10:295.
9. Fife K, Wu J, Squires K, Watts D, Andersen J, Brown DR. Prevalence and persistence of cervical human papillomavirus infection in HIVpositive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 51:274-82.
10. Minkoff H, Zhong Y, Burk R, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency viruspositive women. J Infect Dis 2010; 201:681-90.
11. Dal Maso L, Polesel J, Serraino D, et al. Cancer and AIDS Registries Linkage (CARL) Study. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100:840-7.
12. Chaturvedi A, Madeleine M, Biggar R, Engels E. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120-30.
13. Palefsky JM. Antiretroviral therapy and anal cancer: the good, the bad, and the unknown. Sex Transm Dis 2012; 39:501-3.
14. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87:1365-71.
15. Dauby N, De Wit S, Delforge M, Necsoi C, Clumeck N. Characteristics of non-AIDS defining malignancies in the HAART era : a clinicoepidemiological study. J Int AIDS Soc 2011; 14:16.
16. Howard A, Arnsten J, Lo Y, et al. HER Study Group. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002; 16:2175-82.
17. Luque A, Demeter L, Reichman R. Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. J Infect Dis 1999; 179:1405-9.
18. Swindells S, Evans S, Zackin R, et al. AIDS Clinical Trial Group 722 Study Team. Predictive value of HIV-1 viral load on risk for opportunistic infection. J Acquir Immune Defic Syndr 2002; 30:154-8.
19. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count ≤200 cells/μL? Clin Infect Dis 2010; 51:611-9.
20. Crowley-Nowick P, Ellenberg J, et al. Cytokine profile in genital tract secretions from female adolescents: impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J Infect Dis 2000; 181:939-45.
21. Moscicki A, Ellenberg J, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190:37-45.
22. Nowak R, Gravitt P, Morrison C, et al. Increases in human papillomavirus detection during early HIV infection among women in Zimbabwe . J Infect Dis 2011; 203:1182-91.
23. Zhang Z, Wietgrefe S, Li Q, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci USA 2004; 101:5640-5.
24. Safaeian M, Kiddugavu M, Gravitt P, et al. Determinants of incidence and clearance of high-risk human papillomavirus infections in rural Rakai, Uganda. Cancer Epidemiol Biomarkers Prev 2008; 17:1300-7.
25. Shah K, Solomon L, Daniel R, Cohn S, Vlahov D. Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. J Clin Microbiol 1997; 35:517-9.
26. Bouvard V, Baan R, Straif K, et al. WHO International Agency for Research on Cancer MonographWorking Group. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10:321-2.
27. Clifford G, Gonçalves M, Franceschi S. HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337-44.